APP and Alzheimer disease: One study reported that rapamycin, an mTOR inhibitor, led to a reduced Aβ burden and tau hyperphosphorylation in amyloid precursor protein (APP) presenilin 1 (PS1) (APP/PS1)-expressing AD transgenic mice, which was associated with an increase in the insulin-degrading enzyme (IDE), a known regulator of amyloid pathology in the brain [65].